

22. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *Lancet Diabetes Endocrinol* 2021; 9:653-662.
23. Nicholls SJ, Pavo I, Bhatt DL, et al.; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. *N Engl J Med* 2025; 393:2409-2420.
24. Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2 b Study. *Diabetes Care* 2021; 44:1433-1442.
25. Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. *Nat Commun* 2023; 14:8289.
26. Briand F, Augustin R, Wesche F, et al. Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet-Induced Obese Hamster Model. *Diabetes* 2024; 73 (Supplement_1): 1635-P.
27. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. *Lancet* 2023; 402:529-544.
28. Jastreboff AM, Kaplan LM, Frias JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. *N Engl J Med* 2023; 389:514-526.
29. Mach F, Koskinas KC, Roeters van Lennep JE, et al.; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J* 2025; 46:4359-4378.
30. Cholesterol Treatment Trialists' (CTT) Collaboration; Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015; 385:1397-1405.
31. Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008; 371:117-125.
32. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med* 2015; 372:2387-2397.
33. Giugliano RP, Cannon CP, Blazing MA, et al.; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circulation* 2018; 137:1571-1582.
34. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011; 377:2181-2192.
35. Singh A, Kesani H, Verma S, et al. Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management. *Cureus* 2025; 17:e94134.
36. Monami M, Sesti G, Mannucci E. PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. *Diabetes Obes Metab* 2019; 21:903-908.
37. Imbalzano E, Iardi F, Orlando L, et al. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother* 2023; 9:318-327.
38. Igweonu-Nwakile EO, Ali S, Paul S, et al. A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. *Cureus* 2022; 14:e29140.
39. Leiter LA, Raal FJ, Schwartz GG, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. *Diabetes Obes Metab* 2024; 26:3223-3237.
40. Landmesser U, Ray KK, Raal FJ, et al.; ORION Investigators. Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials. *J Am Soc Nephrol* 2026; doi: 10.1681/ASN.000001006.
41. Cao YX, Liu HH, Dong QT, et al. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. *Diabetes Obes Metab* 2018; 20:1391-1398.
42. Li F, Ye H, Chen L, et al. Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin. *Front Pharmacol* 2025; 16:1554631.
43. Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. *N Engl J Med* 2023; 388:1353-1364.
44. Leiter LA, Banach M, Catapano AL, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. *Diabetes Obes Metab* 2022; 24:868-880.
45. Ray KK, Bloedon L, Li N, Nissen SE; co-authors. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors' reply. *Lancet Diabetes Endocrinol*. 2024; 12:228-229.
46. Stemmer K, Finan B, DiMarchi RD, et al. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. *Adv Drug Deliv Rev* 2020; 159:34-53.
47. O'Brien RC, Abdallah K, Dong X, et al. Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. *J Diabetes* 2026; 18:e70193.
48. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med*. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628.



SAVE
THE DATE

2. kongres diabetologie pro praxi

Praha

12. května 2027



www.diabetologiepraha.cz

SOLEN
Medical Education

